Louise Chen
Stock Analyst at Scotiabank
(3.37)
# 973
Out of 5,148 analysts
296
Total ratings
47.69%
Success rate
3.44%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $33.77 | +18.45% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $248.56 | +6.61% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $62.34 | -3.75% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $121.41 | -1.16% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $790.81 | -2.63% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $16.32 | +390.20% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.05 | +195.08% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $29.70 | -52.86% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $2.71 | +342.80% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $22.83 | +140.91% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $66.37 | -17.13% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.35 | +180.37% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $132.61 | -62.30% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $6.47 | +131.84% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $38.89 | -56.29% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $16.15 | +209.60% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.17 | +227.15% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.42 | +198.59% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.19 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $37.76 | +323.73% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.98 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $234.26 | +2.45% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $27.26 | +65.08% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.09 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.10 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,017.97 | -13.06% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.29 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.75 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.51 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.19 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.50 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.24 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.93 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.69 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.75 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $4.97 | +1,207.85% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.50 | +100.00% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.90 | +259.84% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $24.76 | +101.94% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.24 | +123.21% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.61 | +1,387.60% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.80 | +210,674,057.30% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $219.94 | +17.30% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.20 | +4,066.67% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.24 | +1,512.90% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.09 | +456.24% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $33.77
Upside: +18.45%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $248.56
Upside: +6.61%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $62.34
Upside: -3.75%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $121.41
Upside: -1.16%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $790.81
Upside: -2.63%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $16.32
Upside: +390.20%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.05
Upside: +195.08%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $29.70
Upside: -52.86%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $2.71
Upside: +342.80%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $22.83
Upside: +140.91%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $66.37
Upside: -17.13%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.35
Upside: +180.37%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $132.61
Upside: -62.30%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $6.47
Upside: +131.84%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $38.89
Upside: -56.29%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $16.15
Upside: +209.60%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.17
Upside: +227.15%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.42
Upside: +198.59%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.19
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $37.76
Upside: +323.73%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.98
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $234.26
Upside: +2.45%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $27.26
Upside: +65.08%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.09
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.10
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,017.97
Upside: -13.06%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.29
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.75
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.51
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.19
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.50
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.24
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.93
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.69
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.75
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $4.97
Upside: +1,207.85%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.50
Upside: +100.00%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.90
Upside: +259.84%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $24.76
Upside: +101.94%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.24
Upside: +123.21%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.61
Upside: +1,387.60%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.80
Upside: +210,674,057.30%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $219.94
Upside: +17.30%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.20
Upside: +4,066.67%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.24
Upside: +1,512.90%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $8.09
Upside: +456.24%